Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
February 22nd, 2019
Transgenic lck:eGFP zebrafish express GFP highly in T lymphocytes, and have been used to study T cell development and acute lymphoblastic leukemia. This line can be used to study B cells, which express lck at lower levels. This protocol describes purification of malignant and non-malignant B cells from lck:eGFP zebrafish.
Overview
This study focuses on the use of transgenic lck:eGFP zebrafish to investigate T cell and B cell development, particularly in the context of acute lymphoblastic leukemia (ALL). The zebrafish model allows for the purification of both malignant and non-malignant B cells, providing insights into the adaptive immune system.
Key Study Components
Area of Science
- Neuroscience
- Immunology
- Oncology
Background
- Transgenic lck:eGFP zebrafish express GFP in T lymphocytes.
- These zebrafish can also be used to study B cells, which express lck at lower levels.
- The model is relevant for studying pediatric cancers, particularly B-ALL and T-ALL.
- Dissection techniques are crucial for obtaining thymus and marrow samples.
Purpose of Study
- To explore B cell development and malignancies in zebrafish.
- To provide a model for studying both T and B cell acute lymphoblastic leukemia.
- To enhance understanding of the adaptive immune system.
Methods Used
- Purification of malignant and non-malignant B cells from zebrafish.
- Dissection techniques for obtaining samples.
- Analysis of GFP expression in B and T cells.
- Comparative studies of cancerous and non-cancerous cells.
Main Results
- Many B cells in lck:eGFP zebrafish express low levels of GFP.
- The model allows for the study of both B-ALL and T-ALL.
- Insights gained are relevant to understanding pediatric cancer.
- Refinement of dissection techniques improves sample quality.
Conclusions
- Transgenic lck:eGFP zebrafish are valuable for studying immune cell development.
- The model provides insights into the mechanisms of leukemia.
- Future studies can leverage this model for further research in immunology and oncology.
Frequently Asked Questions
Executive Industry Relevance
The ability to isolate malignant and non-malignant B cells from lck:eGFP zebrafish enables mechanistic de-risking and target validation in hematologic malignancy research. This approach supports predictive confidence in early discovery and translational studies of B cell development and leukemia, directly impacting portfolio decisions in immuno-oncology pipelines. The method provides a scalable platform for dissecting adaptive immune cell biology and malignancy within a genetically tractable vertebrate model.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of B cell and T cell lineage specification in a live vertebrate system.
- Supports mechanistic de-risking of candidate targets implicated in lymphoid malignancies.
- Facilitates comparative analysis of malignant versus non-malignant B cell populations for target validation.
- Provides a platform for evaluating the impact of genetic drivers such as MYC on lymphocyte development.
Screening & Assay Development
- Delivers validated, FACS-purified B and T cell populations for downstream molecular assays.
- Enables reproducible gating strategies to distinguish GFP low (B cells) and GFP high (T cells) populations.
- Supports quantitative assessment of cell-type specific gene expression and biomarker discovery.
- Prepares standardized cell suspensions for high-throughput screening or functional assays.
Translational & Preclinical Research
- Aligns with disease-relevant models of B-ALL and T-ALL for translational biomarker studies.
- Enables continuity from discovery-stage mechanistic studies to preclinical validation of therapeutic hypotheses.
- Supports risk-adjusted advancement of immuno-oncology assets by providing predictive in vivo data.
- Facilitates in vivo transplantation and functional validation of candidate therapies in a vertebrate system.
Pipeline & Workflow Integration
This method integrates into the discovery-to-preclinical continuum by enabling isolation and characterization of lymphocyte populations for hypothesis testing, target validation, and translational research.
- Discovery Biology: Supports hypothesis-driven studies of lymphocyte lineage and malignancy mechanisms.
- Screening: Provides reproducible, quantitative cell sorting outputs for assay development and compound evaluation.
- Analytics: Enables statistical comparison of GFP low and high populations for gene expression and phenotypic analysis.
- Translational Research: Connects mechanistic findings to disease-relevant models of leukemia for biomarker alignment.
- Enterprise Reuse: Establishes a reusable zebrafish platform for ongoing immunology and oncology research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in lymphoid malignancy research.
- Operational Value: Standardizes cell isolation and sorting workflows for reproducibility and scalability.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling early de-risking of targets.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of immuno-oncology assets.
Implementation Considerations
- Requires expertise in zebrafish handling, dissection, and FACS operation.
- Needs access to fluorescence microscopy and flow cytometry infrastructure.
- Demands rigorous gating standardization for cross-study reproducibility.
- Adaptation may be needed for different transgenic lines or tissue sources.
- Sample quality and cell yield depend on technical proficiency and animal age.
Biopharma FAQs
Chapters in this video
0:04
Title
1:05
Non-malignant B and T Lymphocyte Isolation from Transgenic lck:eGFP Fish
2:11
Malignant Lymphocyte Isolation from Double-transgenic rag2:hMYC;lck:eGFP Zebrafish
4:55
Normal or Malignant B Lymphocyte Flow Cytometric Analysis
5:50
Results: Representative Malignant and Non-malignant B Cell GFP Expression in Ick:eGFP Zebrafish
7:44
Conclusion
